A Phase 2 interventional study of altSonflex1-2-3 Dose A and altSonflex1-2-3 Dose B in Diarrhoea, sponsored by GlaxoSmithKline. Completed at 1 site in Kenya. Open to participants aged 39 Weeks to 43 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diarrhea with a site in Kenya — 3 open to participants now, 6 under way, 1 of them phase 3. Diarrhea · Kenya.
Among the 25 studies in Diarrhea with a site in Kenya, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 24th registered.
878 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →3 of the 25 studies in Diarrhea with a site in Kenya are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Kenya
Ages 26 mo–55 mo · Healthy volunteers
University of Washington · Sites in Kenya
Ages 6 mo–24 mo · Healthy volunteers
University of Chicago · Sites in Kenya
Women only · Healthy volunteers
A study can be open while its sites in Kenya have not opened yet or have stopped. Only those recruiting at a site in Kenya →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 39 Weeks to 43 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 5 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 600 across the 21 interventional studies, 2,483 across the 4 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 25 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 6 studies filed under Diarrhea — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Diarrhea with a site in Kenya, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants. The candidate vaccine, altSonflex1-2-3, is currently being evaluated in a Phase 2 age de-escalation (from least vulnerable adult population to most vulnerable paediatric population) clinical study in Kenya, with the aim of identifying a preferred dose, using a 3-dose vaccination schedule in infants from 9 months of age (NCT05073003). This Phase 2 clinical study will evaluate the safety and immunogenicity of an alternative 2-dose vaccination schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 low doses of altSonflex1-2-3 and 2 doses of the measles and rubella vaccine (MR-VAC) one each on Day 1 and Day 169.
Biological: altSonflex1-2-3 Dose A · Biological: MR-VAC
Participants received 2 medium doses of altSonflex1-2-3 and 2 doses of MR-VAC one each on Day 1 and Day 169.
Biological: altSonflex1-2-3 Dose B · Biological: MR-VAC
Participants received 2 high doses of altSonflex1-2-3 and 2 doses of MR-VAC one each on Day 1 and Day 169.
Biological: altSonflex1-2-3 Dose C · Biological: MR-VAC
Participants received 1 dose of the TYPHIBEV vaccine on Day 1 and 1 dose of the Infanrix Hexa vaccine on Day 169, along with 2 doses of MR-VAC on Day 1 and Day 169.
Biological: TYPHIBEV · Combination Product: Infanrix hexa · Biological: MR-VAC
altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
Also known as: Shigella vaccine
altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
Also known as: Shigella vaccine
altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
Also known as: Shigella vaccine
TYPHIBEV administered intramuscularly on Day 1
Also known as: Biological E. Limited's Typhoid Vi-CRM197 conjugate vaccine
Infanrix hexa administered intramuscularly on Day 169
Also known as: GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated) and Haemophilus influenzae type b vaccine (adsorbed)
MR-VAC co-administered subcutaneously on Day 1 and Day 169
Also known as: Serum Institute of India's Measles and rubella vaccine (live)
Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
Time frame: At Day 1 (before administration of Dose 1)
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame: At Day 29 (28 days after administration of Dose 1)
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame: At Day 169 (before administration of Dose 2)
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame: At Day 197 (28 days after administration of Dose 2)
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
Time frame: At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame: At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame: At Day 197 compared to pre-Dose 2 at Day 169
Number of Participants With Solicited Administration Site Events
The solicited administration site events assessed were erythema, pain and swelling.
Time frame: During the 7 days after each study intervention administration (study intervention administered at Day 1 and Day 169)
Number of Participants With Solicited Systemic Events
The solicited systemic event assessed was fever (pyrexia). Fever is defined as temperature ≥38.0°Celsius (C), measured axillary.
Time frame: During the 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
Number of Participants With Unsolicited Adverse Events (AEs)
An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.
Time frame: During the 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
Number of Participants With Serious AEs (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: Day 1 to Day 197
Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: Day 8 compared to baseline (pre-Dose 1 at Day 1)
Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 176
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 169 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: Day 176 compared to pre-Dose 2 at Day 169
The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade Values
Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.
Time frame: Day 8 compared to baseline (before administration of Dose 1 at Day 1)
The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade Values
Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 169 and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.
Time frame: Day 176 compared to pre-Dose 2 at Day 169
Anti-measles IgG Concentrations Expressed as GMCs
Anti-measles IgG concentrations were expressed as GMCs in EU/mL.
Time frame: At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
Anti-rubella IgG Concentrations Expressed as GMCs
Anti-rubella IgG concentrations were expressed as GMCs in EU/mL.
Time frame: At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
Number of Participants Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
Time frame: At Day 197 (28 days after the second MR-VAC vaccination)
Number of Participants Achieving Anti-rubella IgG Concentrations of ≥4 IU/mL and ≥10 IU/mL
Time frame: At Day 197 (28 days after the second MR-VAC vaccination)
| Milestone | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Started | 50 | 50 | 50 | 50 |
| Completed | 47 | 42 | 48 | 48 |
| Not completed | 3 | 8 | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 | 2 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
| ELISA units per milliliter (EU/mL) | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 7.4 (6.5 to 8.3) | 8.1 (7.0 to 9.5) | 8.7 (6.6 to 11.5) | 9.2 (7.3 to 11.7) |
| S. flexneri 1b | 5.5 (4.4 to 6.9) | 8.3 (5.7 to 12.1) | 7.6 (5.6 to 10.4) | 6.1 (4.7 to 7.9) |
| S. flexneri 2a | 5.1 (3.8 to 6.9) | 4.9 (3.4 to 7.1) | 4.6 (3.1 to 6.8) | 4.0 (2.9 to 5.6) |
| S. flexneri 3a | 3.9 (2.9 to 5.2) | 5.1 (3.4 to 7.6) | 4.2 (3.0 to 6.0) | 4.2 (3.0 to 5.7) |
| EU/mL | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 44.6 (32.2 to 61.7) | 66.4 (46.9 to 93.9) | 59.5 (44.7 to 79.1) | 8.7 (7.0 to 10.8) |
| S. flexneri 1b | 20.2 (13.9 to 29.5) | 48.7 (35.1 to 67.7) | 30.5 (20.4 to 45.6) | 6.5 (4.8 to 8.9) |
| S. flexneri 2a | 71.3 (43.1 to 117.8) | 98.4 (64.0 to 151.3) | 77.1 (53.8 to 110.5) | 4.5 (3.1 to 6.7) |
| S. flexneri 3a | 11.0 (7.1 to 16.9) | 24.1 (15.4 to 37.9) | 16.6 (11.2 to 24.6) | 5.2 (3.5 to 7.6) |
| EU/mL | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 26.0 (16.4 to 41.3) | 34.7 (22.9 to 52.6) | 33.5 (23.3 to 48.3) | 10.6 (7.1 to 15.8) |
| S. flexneri 1b | 12.0 (8.3 to 17.2) | 16.2 (11.2 to 23.4) | 14.4 (10.0 to 20.9) | 13.2 (9.0 to 19.3) |
| S. flexneri 2a | 11.2 (7.2 to 17.5) | 13.4 (8.8 to 20.6) | 9.6 (6.2 to 14.8) | 6.0 (4.0 to 8.9) |
| S. flexneri 3a | 6.0 (4.0 to 9.0) | 10.1 (6.8 to 14.9) | 8.0 (5.4 to 12.0) | 8.4 (5.5 to 12.7) |
| EU/mL | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 802.1 (521.4 to 1234.0) | 1320.3 (903.8 to 1928.8) | 1080.7 (675.7 to 1728.5) | 10.6 (7.2 to 15.6) |
| S. flexneri 1b | 32.0 (23.9 to 42.9) | 39.8 (28.3 to 55.9) | 32.3 (22.5 to 46.3) | 12.4 (8.5 to 18.3) |
| S. flexneri 2a | 83.5 (58.0 to 120.1) | 92.8 (63.7 to 135.1) | 75.3 (52.3 to 108.4) | 5.1 (3.5 to 7.3) |
| S. flexneri 3a | 19.8 (13.4 to 29.2) | 31.9 (23.0 to 44.3) | 19.1 (12.4 to 29.5) | 7.9 (5.1 to 12.1) |
S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 32 | 31 | 35 | 0 |
| S. flexneri 1b | 21 | 30 | 27 | 3 |
| S. flexneri 2a | 37 | 38 | 39 | 3 |
| S. flexneri 3a | 19 | 23 | 22 | 4 |
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 42 | 42 | 43 | 5 |
| S. flexneri 1b | 28 | 22 | 22 | 11 |
| S. flexneri 2a | 40 | 37 | 37 | 8 |
| S. flexneri 3a | 22 | 24 | 27 | 12 |
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| S. sonnei | 36 | 39 | 41 | 0 |
| S. flexneri 1b | 13 | 8 | 8 | 1 |
| S. flexneri 2a | 31 | 30 | 29 | 0 |
| S. flexneri 3a | 16 | 15 | 7 | 3 |
The solicited administration site events assessed were erythema, pain and swelling.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Erythema, post-Dose 1 | 7 | 6 | 6 | 3 |
| Erythema, post-Dose 2 | 3 | 3 | 7 | 4 |
| Pain, post-Dose 1 | 11 | 14 | 17 | 3 |
| Pain, post-Dose 2 | 11 | 13 | 11 | 13 |
| Swelling, post-Dose 1 | 7 | 9 | 12 | 2 |
| Swelling, post-Dose 2 | 7 | 10 | 7 | 6 |
The solicited systemic event assessed was fever (pyrexia). Fever is defined as temperature ≥38.0°Celsius (C), measured axillary.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Fever, post-Dose 1 | 10 | 6 | 9 | 7 |
| Fever, post-Dose 2 | 4 | 10 | 5 | 6 |
An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Unsolicited AEs, post-study intervention administered at Day 1 | 23 | 23 | 24 | 24 |
| Unsolicited AEs, post-study intervention administered at Day 169 | 9 | 14 | 12 | 17 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Number of Participants With Serious AEs (SAEs) | 1 | 0 | 0 | 0 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| ALT, Below, Below | 0 | 0 | 1 | 0 |
| ALT, Below, Within | 0 | 0 | 0 | 0 |
| ALT, Below, Above | 0 | 0 | 0 | 0 |
| ALT, Within, Below | 0 | 1 | 0 | 0 |
| ALT, Within, Within | 48 | 43 | 47 | 47 |
| ALT, Within, Above | 1 | 1 | 1 | 1 |
| ALT, Above, Below | 0 | 0 | 0 | 0 |
| ALT, Above, Within | 0 | 1 | 1 | 1 |
| ALT, Above, Above | 0 | 0 | 0 | 0 |
| AST, Below, Below | 0 | 0 | 0 | 0 |
| AST, Below, Within | 0 | 0 | 0 | 0 |
| AST, Below, Above | 0 | 0 | 0 | 0 |
| AST, Within, Below | 0 | 0 | 0 | 0 |
| AST, Within, Within | 48 | 45 | 50 | 48 |
| AST, Within, Above | 0 | 0 | 0 | 1 |
| AST, Above, Below | 0 | 0 | 0 | 0 |
| AST, Above, Within | 0 | 1 | 0 | 0 |
| AST, Above, Above | 1 | 0 | 0 | 0 |
| Creatinine, Below, Below | 49 | 46 | 50 | 49 |
| Creatinine, Below, Within | 0 | 0 | 0 | 0 |
| Creatinine, Below, Above | 0 | 0 | 0 | 0 |
| Creatinine, Within, Below | 0 | 0 | 0 | 0 |
| Creatinine, Within, Within | 0 | 0 | 0 | 0 |
| Creatinine, Within, Above | 0 | 0 | 0 | 0 |
| Creatinine, Above, Below | 0 | 0 | 0 | 0 |
| Creatinine, Above, Within | 0 | 0 | 0 | 0 |
| Creatinine, Above, Above | 0 | 0 | 0 | 0 |
| Potassium, Below, Below | 0 | 0 | 0 | 0 |
| Potassium, Below, Within | 0 | 0 | 0 | 0 |
| Potassium, Below, Above | 0 | 0 | 0 | 0 |
| Potassium, Within, Below | 1 | 0 | 0 | 0 |
| Potassium, Within, Within | 48 | 46 | 50 | 49 |
| Potassium, Within, Above | 0 | 0 | 0 | 0 |
| Potassium, Above, Below | 0 | 0 | 0 | 0 |
| Potassium, Above, Within | 0 | 0 | 0 | 0 |
| Potassium, Above, Above | 0 | 0 | 0 | 0 |
| Sodium, Below, Below | 0 | 0 | 0 | 0 |
| Sodium, Below, Within | 1 | 1 | 0 | 0 |
| Sodium, Below, Above | 0 | 0 | 0 | 0 |
| Sodium, Within, Below | 0 | 1 | 0 | 0 |
| Sodium, Within, Within | 31 | 35 | 37 | 35 |
| Sodium, Within, Above | 10 | 6 | 7 | 6 |
| Sodium, Above, Below | 0 | 0 | 0 | 0 |
| Sodium, Above, Within | 4 | 3 | 6 | 5 |
| Sodium, Above, Above | 3 | 0 | 0 | 3 |
| Urea, Below, Below | 23 | 29 | 20 | 24 |
| Urea, Below, Within | 11 | 1 | 7 | 7 |
| Urea, Below, Above | 0 | 0 | 0 | 0 |
| Urea, Within, Below | 6 | 6 | 10 | 10 |
| Urea, Within, Within | 9 | 9 | 13 | 8 |
| Urea, Within, Above | 0 | 1 | 0 | 0 |
| Urea, Above, Below | 0 | 0 | 0 | 0 |
| Urea, Above, Within | 0 | 0 | 0 | 0 |
| Urea, Above, Above | 0 | 0 | 0 | 0 |
| Basophils, Below, Below | 0 | 0 | 0 | 0 |
| Basophils, Below, Within | 0 | 0 | 0 | 0 |
| Basophils, Below, Above | 0 | 0 | 0 | 0 |
| Basophils, Within, Below | 0 | 0 | 0 | 0 |
| Basophils, Within, Within | 27 | 28 | 33 | 32 |
| Basophils, Within, Above | 3 | 6 | 4 | 4 |
| Basophils, Above, Below | 0 | 0 | 0 | 0 |
| Basophils, Above, Within | 11 | 8 | 9 | 8 |
| Basophils, Above, Above | 8 | 4 | 4 | 5 |
| Eosinophils, Below, Below | 0 | 0 | 0 | 0 |
| Eosinophils, Below, Within | 1 | 0 | 1 | 0 |
| Eosinophils, Below, Above | 0 | 0 | 0 | 0 |
| Eosinophils, Within, Below | 2 | 3 | 0 | 0 |
| Eosinophils, Within, Within | 40 | 40 | 48 | 45 |
| Eosinophils, Within, Above | 2 | 1 | 0 | 2 |
| Eosinophils, Above, Below | 0 | 0 | 0 | 0 |
| Eosinophils, Above, Within | 3 | 0 | 0 | 1 |
| Eosinophils, Above, Above | 1 | 2 | 1 | 1 |
| Erythrocytes, Below, Below | 0 | 0 | 0 | 0 |
| Erythrocytes, Below, Within | 0 | 0 | 0 | 0 |
| Erythrocytes, Below, Above | 0 | 0 | 0 | 0 |
| Erythrocytes, Within, Below | 1 | 1 | 0 | 1 |
| Erythrocytes, Within, Within | 25 | 28 | 28 | 29 |
| Erythrocytes, Within, Above | 7 | 3 | 4 | 3 |
| Erythrocytes, Above, Below | 0 | 0 | 0 | 0 |
| Erythrocytes, Above, Within | 1 | 6 | 6 | 4 |
| Erythrocytes, Above, Above | 15 | 8 | 12 | 12 |
| Hematocrit, Below, Below | 0 | 0 | 1 | 1 |
| Hematocrit, Below, Within | 2 | 3 | 0 | 3 |
| Hematocrit, Below, Above | 0 | 0 | 0 | 0 |
| Hematocrit, Within, Below | 1 | 3 | 0 | 0 |
| Hematocrit, Within, Within | 38 | 36 | 38 | 34 |
| Hematocrit, Within, Above | 6 | 0 | 5 | 4 |
| Hematocrit, Above, Below | 0 | 0 | 0 | 0 |
| Hematocrit, Above, Within | 1 | 1 | 3 | 4 |
| Hematocrit, Above, Above | 1 | 3 | 3 | 3 |
| Hemoglobin, Below, Below | 5 | 3 | 4 | 2 |
| Hemoglobin, Below, Within | 1 | 3 | 2 | 4 |
| Hemoglobin, Below, Above | 0 | 0 | 0 | 0 |
| Hemoglobin, Within, Below | 1 | 4 | 1 | 1 |
| Hemoglobin, Within, Within | 40 | 32 | 37 | 38 |
| Hemoglobin, Within, Above | 1 | 1 | 2 | 2 |
| Hemoglobin, Above, Below | 0 | 0 | 0 | 0 |
| Hemoglobin, Above, Within | 1 | 2 | 2 | 2 |
| Hemoglobin, Above, Above | 0 | 1 | 2 | 0 |
| Leukocytes, Below, Below | 0 | 0 | 3 | 1 |
| Leukocytes, Below, Within | 1 | 2 | 3 | 2 |
| Leukocytes, Below, Above | 0 | 0 | 0 | 0 |
| Leukocytes, Within, Below | 4 | 1 | 1 | 2 |
| Leukocytes, Within, Within | 31 | 30 | 31 | 33 |
| Leukocytes, Within, Above | 3 | 4 | 4 | 1 |
| Leukocytes, Above, Below | 0 | 0 | 0 | 0 |
| Leukocytes, Above, Within | 5 | 9 | 4 | 7 |
| Leukocytes, Above, Above | 5 | 0 | 4 | 3 |
| Lymphocytes, Below, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Below, Within | 0 | 0 | 0 | 0 |
| Lymphocytes, Below, Above | 0 | 0 | 0 | 0 |
| Lymphocytes, Within, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Within, Within | 30 | 30 | 26 | 33 |
| Lymphocytes, Within, Above | 5 | 3 | 8 | 5 |
| Lymphocytes, Above, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Above, Within | 6 | 6 | 7 | 6 |
| Lymphocytes, Above, Above | 8 | 7 | 9 | 5 |
| Monocytes, Below, Below | 0 | 1 | 0 | 0 |
| Monocytes, Below, Within | 2 | 3 | 0 | 4 |
| Monocytes, Below, Above | 0 | 0 | 0 | 0 |
| Monocytes, Within, Below | 1 | 0 | 1 | 1 |
| Monocytes, Within, Within | 27 | 29 | 39 | 27 |
| Monocytes, Within, Above | 12 | 8 | 6 | 11 |
| Monocytes, Above, Below | 0 | 0 | 0 | 0 |
| Monocytes, Above, Within | 2 | 2 | 3 | 4 |
| Monocytes, Above, Above | 5 | 3 | 1 | 2 |
| Neutrophils, Below, Below | 3 | 3 | 2 | 7 |
| Neutrophils, Below, Within | 4 | 6 | 2 | 3 |
| Neutrophils, Below, Above | 0 | 0 | 0 | 0 |
| Neutrophils, Within, Below | 10 | 1 | 8 | 6 |
| Neutrophils, Within, Within | 31 | 33 | 35 | 33 |
| Neutrophils, Within, Above | 1 | 1 | 1 | 0 |
| Neutrophils, Above, Below | 0 | 0 | 0 | 0 |
| Neutrophils, Above, Within | 0 | 2 | 2 | 0 |
| Neutrophils, Above, Above | 0 | 0 | 0 | 0 |
| Platelets, Below, Below | 0 | 0 | 0 | 0 |
| Platelets, Below, Within | 0 | 0 | 1 | 0 |
| Platelets, Below, Above | 0 | 0 | 0 | 0 |
| Platelets, Within, Below | 0 | 0 | 0 | 0 |
| Platelets, Within, Within | 7 | 5 | 10 | 24 |
| Platelets, Within, Above | 9 | 7 | 8 | 3 |
| Platelets, Above, Below | 0 | 0 | 0 | 0 |
| Platelets, Above, Within | 8 | 10 | 2 | 11 |
| Platelets, Above, Above | 25 | 24 | 29 | 11 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 169 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| ALT, Below, Below | 0 | 1 | 1 | 0 |
| ALT, Below, Within | 0 | 0 | 0 | 0 |
| ALT, Below, Above | 0 | 0 | 0 | 0 |
| ALT, Within, Below | 0 | 0 | 0 | 0 |
| ALT, Within, Within | 44 | 42 | 44 | 46 |
| ALT, Within, Above | 1 | 0 | 0 | 1 |
| ALT, Above, Below | 0 | 0 | 0 | 0 |
| ALT, Above, Within | 0 | 0 | 0 | 1 |
| ALT, Above, Above | 1 | 0 | 1 | 1 |
| AST, Below, Below | 0 | 0 | 0 | 0 |
| AST, Below, Within | 0 | 0 | 0 | 0 |
| AST, Below, Above | 0 | 0 | 0 | 0 |
| AST, Within, Below | 0 | 0 | 0 | 0 |
| AST, Within, Within | 43 | 41 | 45 | 47 |
| AST, Within, Above | 0 | 0 | 0 | 1 |
| AST, Above, Below | 0 | 0 | 0 | 0 |
| AST, Above, Within | 1 | 2 | 0 | 0 |
| AST, Above, Above | 2 | 0 | 1 | 1 |
| Creatinine, Below, Below | 45 | 43 | 45 | 47 |
| Creatinine, Below, Within | 0 | 0 | 1 | 1 |
| Creatinine, Below, Above | 1 | 0 | 0 | 0 |
| Creatinine, Within, Below | 0 | 0 | 0 | 1 |
| Creatinine, Within, Within | 0 | 0 | 0 | 0 |
| Creatinine, Within, Above | 0 | 0 | 0 | 0 |
| Creatinine, Above, Below | 0 | 0 | 0 | 0 |
| Creatinine, Above, Within | 0 | 0 | 0 | 0 |
| Creatinine, Above, Above | 0 | 0 | 0 | 0 |
| Potassium, Below, Below | 0 | 0 | 0 | 0 |
| Potassium, Below, Within | 0 | 0 | 0 | 0 |
| Potassium, Below, Above | 0 | 0 | 0 | 0 |
| Potassium, Within, Below | 0 | 0 | 0 | 0 |
| Potassium, Within, Within | 11 | 11 | 6 | 17 |
| Potassium, Within, Above | 9 | 10 | 14 | 13 |
| Potassium, Above, Below | 0 | 0 | 0 | 0 |
| Potassium, Above, Within | 9 | 6 | 6 | 2 |
| Potassium, Above, Above | 17 | 16 | 20 | 17 |
| Sodium, Below, Below | 0 | 0 | 0 | 0 |
| Sodium, Below, Within | 0 | 0 | 0 | 0 |
| Sodium, Below, Above | 0 | 0 | 0 | 0 |
| Sodium, Within, Below | 0 | 0 | 0 | 0 |
| Sodium, Within, Within | 37 | 38 | 40 | 39 |
| Sodium, Within, Above | 6 | 3 | 2 | 2 |
| Sodium, Above, Below | 0 | 0 | 0 | 0 |
| Sodium, Above, Within | 3 | 2 | 4 | 8 |
| Sodium, Above, Above | 0 | 0 | 0 | 0 |
| Urea, Below, Below | 17 | 17 | 16 | 19 |
| Urea, Below, Within | 11 | 4 | 9 | 11 |
| Urea, Below, Above | 0 | 0 | 0 | 0 |
| Urea, Within, Below | 7 | 4 | 6 | 10 |
| Urea, Within, Within | 11 | 18 | 15 | 9 |
| Urea, Within, Above | 0 | 0 | 0 | 0 |
| Urea, Above, Below | 0 | 0 | 0 | 0 |
| Urea, Above, Within | 0 | 0 | 0 | 0 |
| Urea, Above, Above | 0 | 0 | 0 | 0 |
| Basophils, Below, Below | 0 | 0 | 0 | 0 |
| Basophils, Below, Within | 0 | 0 | 0 | 0 |
| Basophils, Below, Above | 0 | 0 | 0 | 0 |
| Basophils, Within, Below | 1 | 0 | 0 | 0 |
| Basophils, Within, Within | 39 | 37 | 43 | 45 |
| Basophils, Within, Above | 2 | 2 | 1 | 2 |
| Basophils, Above, Below | 0 | 0 | 0 | 0 |
| Basophils, Above, Within | 1 | 2 | 2 | 1 |
| Basophils, Above, Above | 3 | 2 | 0 | 1 |
| Eosinophils, Below, Below | 0 | 0 | 0 | 0 |
| Eosinophils, Below, Within | 0 | 1 | 0 | 1 |
| Eosinophils, Below, Above | 0 | 0 | 0 | 0 |
| Eosinophils, Within, Below | 0 | 2 | 0 | 0 |
| Eosinophils, Within, Within | 38 | 29 | 40 | 39 |
| Eosinophils, Within, Above | 2 | 2 | 4 | 2 |
| Eosinophils, Above, Below | 0 | 0 | 0 | 0 |
| Eosinophils, Above, Within | 2 | 0 | 1 | 5 |
| Eosinophils, Above, Above | 4 | 9 | 1 | 2 |
| Erythrocytes, Below, Below | 0 | 0 | 0 | 0 |
| Erythrocytes, Below, Within | 0 | 0 | 0 | 0 |
| Erythrocytes, Below, Above | 0 | 0 | 0 | 0 |
| Erythrocytes, Within, Below | 0 | 0 | 0 | 0 |
| Erythrocytes, Within, Within | 29 | 31 | 28 | 28 |
| Erythrocytes, Within, Above | 2 | 3 | 3 | 2 |
| Erythrocytes, Above, Below | 0 | 0 | 0 | 0 |
| Erythrocytes, Above, Within | 3 | 3 | 5 | 6 |
| Erythrocytes, Above, Above | 12 | 6 | 10 | 13 |
| Hematocrit, Below, Below | 0 | 0 | 1 | 1 |
| Hematocrit, Below, Within | 0 | 1 | 2 | 1 |
| Hematocrit, Below, Above | 0 | 0 | 0 | 0 |
| Hematocrit, Within, Below | 1 | 1 | 1 | 1 |
| Hematocrit, Within, Within | 32 | 36 | 33 | 33 |
| Hematocrit, Within, Above | 4 | 2 | 3 | 3 |
| Hematocrit, Above, Below | 0 | 0 | 0 | 0 |
| Hematocrit, Above, Within | 2 | 1 | 4 | 6 |
| Hematocrit, Above, Above | 7 | 2 | 2 | 4 |
| Hemoglobin, Below, Below | 2 | 6 | 4 | 6 |
| Hemoglobin, Below, Within | 1 | 1 | 2 | 1 |
| Hemoglobin, Below, Above | 0 | 0 | 0 | 0 |
| Hemoglobin, Within, Below | 0 | 1 | 1 | 1 |
| Hemoglobin, Within, Within | 35 | 31 | 38 | 35 |
| Hemoglobin, Within, Above | 2 | 1 | 1 | 2 |
| Hemoglobin, Above, Below | 0 | 0 | 0 | 0 |
| Hemoglobin, Above, Within | 4 | 2 | 0 | 1 |
| Hemoglobin, Above, Above | 2 | 1 | 0 | 3 |
| Leukocytes, Below, Below | 0 | 1 | 0 | 1 |
| Leukocytes, Below, Within | 1 | 2 | 4 | 2 |
| Leukocytes, Below, Above | 0 | 0 | 0 | 0 |
| Leukocytes, Within, Below | 1 | 0 | 0 | 0 |
| Leukocytes, Within, Within | 30 | 32 | 28 | 40 |
| Leukocytes, Within, Above | 4 | 3 | 6 | 3 |
| Leukocytes, Above, Below | 0 | 0 | 0 | 0 |
| Leukocytes, Above, Within | 5 | 2 | 3 | 1 |
| Leukocytes, Above, Above | 5 | 3 | 5 | 2 |
| Lymphocytes, Below, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Below, Within | 0 | 0 | 0 | 0 |
| Lymphocytes, Below, Above | 0 | 0 | 0 | 0 |
| Lymphocytes, Within, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Within, Within | 28 | 33 | 25 | 35 |
| Lymphocytes, Within, Above | 7 | 3 | 7 | 9 |
| Lymphocytes, Above, Below | 0 | 0 | 0 | 0 |
| Lymphocytes, Above, Within | 2 | 2 | 4 | 2 |
| Lymphocytes, Above, Above | 9 | 5 | 10 | 3 |
| Monocytes, Below, Below | 0 | 0 | 0 | 0 |
| Monocytes, Below, Within | 0 | 0 | 0 | 0 |
| Monocytes, Below, Above | 0 | 0 | 0 | 0 |
| Monocytes, Within, Below | 0 | 0 | 0 | 0 |
| Monocytes, Within, Within | 36 | 36 | 38 | 42 |
| Monocytes, Within, Above | 3 | 3 | 3 | 5 |
| Monocytes, Above, Below | 0 | 0 | 0 | 0 |
| Monocytes, Above, Within | 7 | 1 | 4 | 2 |
| Monocytes, Above, Above | 0 | 3 | 1 | 0 |
| Neutrophils, Below, Below | 2 | 2 | 3 | 0 |
| Neutrophils, Below, Within | 4 | 3 | 0 | 7 |
| Neutrophils, Below, Above | 0 | 0 | 0 | 0 |
| Neutrophils, Within, Below | 2 | 6 | 2 | 2 |
| Neutrophils, Within, Within | 35 | 32 | 40 | 38 |
| Neutrophils, Within, Above | 0 | 0 | 0 | 1 |
| Neutrophils, Above, Below | 0 | 0 | 0 | 0 |
| Neutrophils, Above, Within | 3 | 0 | 1 | 1 |
| Neutrophils, Above, Above | 0 | 0 | 0 | 0 |
| Platelets, Below, Below | 0 | 0 | 0 | 0 |
| Platelets, Below, Within | 0 | 0 | 0 | 0 |
| Platelets, Below, Above | 1 | 1 | 1 | 0 |
| Platelets, Within, Below | 0 | 0 | 0 | 0 |
| Platelets, Within, Within | 7 | 5 | 6 | 20 |
| Platelets, Within, Above | 10 | 6 | 12 | 12 |
| Platelets, Above, Below | 0 | 0 | 0 | 0 |
| Platelets, Above, Within | 3 | 4 | 3 | 3 |
| Platelets, Above, Above | 25 | 27 | 24 | 14 |
Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| ALT, Grade 0, Grade 0 | 49 | 45 | 50 | 48 |
| ALT, Grade 0, Grade 1 | 0 | 1 | 0 | 1 |
| AST, Grade 0, Grade 0 | 49 | 46 | 50 | 49 |
| Creatinine, Grade 0, Grade 0 | 49 | 46 | 50 | 49 |
| Hemoglobin, Grade 0, Grade 0 | 42 | 36 | 43 | 42 |
| Hemoglobin, Grade 0, Grade 1 | 1 | 4 | 1 | 1 |
| Hemoglobin, Grade 1, Grade 0 | 1 | 3 | 2 | 4 |
| Hemoglobin, Grade 1, Grade 1 | 5 | 2 | 4 | 2 |
| Hemoglobin, Grade 2, Grade 2 | 0 | 1 | 0 | 0 |
| Neutrophils Decrease, Grade 0, Grade 0 | 32 | 36 | 38 | 33 |
| Neutrophils Decrease, Grade 0, Grade 1 | 8 | 1 | 8 | 6 |
| Neutrophils Decrease, Grade 1, Grade 0 | 1 | 5 | 2 | 2 |
| Neutrophils Decrease, Grade 1, Grade 1 | 1 | 2 | 1 | 5 |
| Neutrophils Decrease, Grade 1, Grade 2 | 0 | 0 | 0 | 1 |
| Neutrophils Decrease, Grade 1, Grade 3 | 0 | 1 | 0 | 1 |
| Neutrophils Decrease, Grade 1, Grade 4 | 1 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 2, Grade 0 | 2 | 0 | 0 | 1 |
| Neutrophils Decrease, Grade 2, Grade 1 | 1 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 3, Grade 0 | 1 | 1 | 0 | 0 |
| Neutrophils Decrease, Grade 3, Grade 1 | 0 | 0 | 1 | 0 |
| Platelets Decrease, Grade 0, Grade 0 | 49 | 46 | 49 | 49 |
| Platelets Decrease, Grade 1, Grade 0 | 0 | 0 | 1 | 0 |
| WBC Decrease, Grade 0, Grade 0 | 44 | 43 | 43 | 44 |
| WBC Decrease, Grade 0, Grade 1 | 4 | 1 | 1 | 2 |
| WBC Decrease, Grade 1, Grade 0 | 1 | 2 | 3 | 2 |
| WBC Decrease, Grade 1, Grade 1 | 0 | 0 | 3 | 1 |
Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 169 and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| ALT, Grade 0, Grade 0 | 45 | 43 | 45 | 48 |
| ALT, Grade 0, Grade 1 | 0 | 0 | 0 | 1 |
| ALT, Grade 1, Grade 0 | 1 | 0 | 0 | 0 |
| ALT, Grade 1, Grade 2 | 0 | 0 | 1 | 0 |
| AST, Grade 0, Grade 0 | 45 | 43 | 45 | 48 |
| AST, Grade 1, Grade 0 | 1 | 0 | 0 | 1 |
| AST, Grade 1, Grade 1 | 0 | 0 | 1 | 0 |
| Creatinine, Grade 0, Grade 0 | 45 | 43 | 46 | 48 |
| Creatinine, Grade 0, Grade 2 | 1 | 0 | 0 | 1 |
| Hemoglobin, Grade 0, Grade 0 | 43 | 35 | 39 | 41 |
| Hemoglobin, Grade 0, Grade 1 | 0 | 1 | 1 | 1 |
| Hemoglobin, Grade 1, Grade 0 | 1 | 1 | 2 | 1 |
| Hemoglobin, Grade 1, Grade 1 | 1 | 3 | 0 | 2 |
| Hemoglobin, Grade 1, Grade 2 | 0 | 1 | 2 | 3 |
| Hemoglobin, Grade 2, Grade 1 | 0 | 2 | 2 | 0 |
| Hemoglobin, Grade 2, Grade 2 | 1 | 0 | 0 | 0 |
| Hemoglobin, Grade 2, Grade 3 | 0 | 0 | 0 | 1 |
| Neutrophils Decrease, Grade 0, Grade 0 | 38 | 32 | 41 | 41 |
| Neutrophils Decrease, Grade 0, Grade 1 | 2 | 6 | 2 | 1 |
| Neutrophils Decrease, Grade 1, Grade 0 | 2 | 2 | 0 | 7 |
| Neutrophils Decrease, Grade 1, Grade 1 | 2 | 0 | 3 | 0 |
| Neutrophils Decrease, Grade 1, Grade 2 | 0 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 1, Grade 3 | 0 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 1, Grade 4 | 0 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 2, Grade 0 | 2 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 2, Grade 1 | 0 | 0 | 0 | 0 |
| Neutrophils Decrease, Grade 2, Grade 2 | 0 | 1 | 0 | 0 |
| Neutrophils Decrease, Grade 3, Grade 0 | 0 | 1 | 0 | 0 |
| Neutrophils Decrease, Grade 3, Grade 1 | 0 | 1 | 0 | 0 |
| Platelets Decrease, Grade 0, Grade 0 | 45 | 42 | 45 | 49 |
| Platelets Decrease, Grade 1, Grade 0 | 1 | 1 | 1 | 0 |
| WBC Decrease, Grade 0, Grade 0 | 44 | 40 | 42 | 46 |
| WBC Decrease, Grade 0, Grade 1 | 1 | 0 | 0 | 0 |
| WBC Decrease, Grade 1, Grade 0 | 1 | 2 | 4 | 2 |
| WBC Decrease, Grade 1, Grade 1 | 0 | 1 | 0 | 1 |
Anti-measles IgG concentrations were expressed as GMCs in EU/mL.
| EU/mL | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Day 1 | 25.4 (24.6 to 26.2) | 25.0 (25.0 to 25.0) | 25.5 (24.5 to 26.4) | 25.8 (24.2 to 27.5) |
| Day 197 | 1005.0 (855.0 to 1181.3) | 835.6 (685.7 to 1018.3) | 923.9 (783.7 to 1089.0) | 954.1 (836.2 to 1088.6) |
Anti-rubella IgG concentrations were expressed as GMCs in EU/mL.
| EU/mL | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Day 1 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.4) | 1.1 (1.0 to 1.2) |
| Day 197 | 91.1 (84.4 to 98.3) | 78.3 (68.2 to 89.8) | 85.1 (76.9 to 94.2) | 84.4 (77.7 to 91.7) |
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| >= 150 mIU/mL | 44 | 41 | 44 | 45 |
| >= 200 mIU/mL | 44 | 41 | 44 | 45 |
| Participants | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| >= 4 IU/mL | 44 | 42 | 44 | 45 |
| >= 10 IU/mL | 44 | 41 | 44 | 45 |
Collected over Solicited AEs: within 7 days after any vaccination. Unsolicited AEs: within 28 days after any vaccination. All-cause mortality and SAEs: From Day 1 until Day 197.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| altSonflex1-2-3 Low Dose Group | 0/50 (0%) | 1/50 (2%) | 41/50 (82%) |
| altSonflex1-2-3 Medium Dose Group | 0/50 (0%) | 0/50 (0%) | 35/50 (70%) |
| altSonflex1-2-3 High Dose Group | 0/50 (0%) | 0/50 (0%) | 42/50 (84%) |
| Control Group | 0/50 (0%) | 0/50 (0%) | 40/50 (80%) |
| Event | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/50 | 0/50 | 0/50 | 0/50 |
| Event | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group |
|---|---|---|---|---|
| Administration site painGeneral disorders | 15/50 | 19/50 | 23/50 | 15/50 |
| Administration site swellingGeneral disorders | 12/50 | 13/50 | 18/50 | 8/50 |
| Upper respiratory tract infectionInfections and infestations | 8/50 | 8/50 | 6/50 | 13/50 |
| PyrexiaGeneral disorders | 12/50 | 12/50 | 9/50 | 10/50 |
| RhinitisInfections and infestations | 5/50 | 8/50 | 8/50 | 12/50 |
| Administration site erythemaGeneral disorders | 8/50 | 7/50 | 10/50 | 7/50 |
| GastroenteritisInfections and infestations | 4/50 | 5/50 | 2/50 | 6/50 |
| TonsillitisInfections and infestations | 5/50 | 1/50 | 4/50 | 1/50 |
| AmoebiasisInfections and infestations | 0/50 | 4/50 | 3/50 | 0/50 |
| DiarrhoeaGastrointestinal disorders | 3/50 | 4/50 | 3/50 | 3/50 |
| Age, Continuous(Months) | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group | Total |
|---|---|---|---|---|---|
| Mean | 9.3 ± 0.5 | 9.3 ± 0.5 | 9.3 ± 0.5 | 9.3 ± 0.5 | 9.3 ± 0.5 |
| Sex: Female, Male(Participants) | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group | Total |
|---|---|---|---|---|---|
| Female | 29 | 21 | 27 | 35 | 112 |
| Male | 21 | 29 | 23 | 15 | 88 |
| Race/Ethnicity, Customized(Participants) | altSonflex1-2-3 Low Dose Group | altSonflex1-2-3 Medium Dose Group | altSonflex1-2-3 High Dose Group | Control Group | Total |
|---|---|---|---|---|---|
| BLACK OR AFRICAN AMERICAN | 50 | 50 | 50 | 50 | 200 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Nov 2024 to primary completion in Oct 2025, 11 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 24 industry-sponsored phase 2 interventional studies under Diarrhea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 20. This study's 11 months is below that.
Counting every sponsor, half of 47 studies reached it within 15 months; a quarter within 11 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.